tions has increased the possibilities of carrier determination. However, problems may occur because of alternative splicing events. Here we present a family with a DMD patient characterised by a deletion of exons 45 to 54. At the mRNA level we detected a corresponding altered fragment which served for carrier determination. The mother and the sister of the patient showed the same altered dystrophin mRNA fragment as the patient and are therefore carriers. In the mother two additional altered dystrophin mRNA fragments were detectable, obviously resulting from alternative splicing in the normal allele. The grandmother and two other related females of the patient possess only the normal mRNA fragment. In a further female we detected an altered fragment owing to an mRNA deletion of exon 44. This fragment is created either by alternative splicing or a new mutation. Therefore, the carrier status of this female is still ambiguous indicating problems in carrier determination by the method of dystrophin mRNA analysis. (7 Med Genet 1993; 30:206- Figure 7 The diagram summarises all detectable DNA and mRNA deletio region of exons 43 to 58. Shaded boxes represent exons which were amplified genomic DNA. Regions of dystrophin transcript which were amplified by RI designated beneath the exon diagram (set 7 and set 8). Black bar represents of DNA deletion identified with cDNA probes cfS6a,b and PCR of genomic Shaded bars designate the extent of all detectable mRNA deletions in the fa; members tested in our study. Effects on the translational reading frame are i the right of the diagram.
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upstream of the human dystrophin gene (DMD). Nucleic
